Australian Study for the Prevention through Immunisation of Cardiovascular Events
AUSPICE is a randomised, placebo-controlled trial to determine if pneumococcal vaccination decreases the incidence of major cardiovascular disease (CVD) events related to hardening of arteries (atherosclerosis), namely heart attacks (fatal and non-fatal acute coronary syndromes) and the most common form of stroke.
4,725 study participants were recruited through a mail-out, contracted through the Department of Human Services, for six Australian sites (Newcastle, Melbourne, Central Coast, Canberra, Perth and Adelaide) and through advertising on social media. The participants, randomly allocated to either pneumococcal vaccine or placebo treatment, were aged 55–60 years of age at enrolment with no self-reported prior heart attack or stroke events, but had at least 2 cardiovascular risk factors: high cholesterol, high blood pressure, or obesity. From 35,000 letters sent to people living in Melbourne, CCRET Clinical Trials Centre screened 2,594 potential participants and randomised 812 participants to the study.
During 2020 the study coordinating centre, located at the School of Medicine and Public Health, University of Newcastle, NSW, will ascertain the outcomes of subjects using data linkage to health records at 4 years post enrolment.
The study is conducted by University of Newcastle and Monash University with funding from the NHMRC.
Roseanne Peel, Shu Ren, Alexis Hure, Tiffany‐Jane Evans, Catherine A D'Este, Walter P Abhayaratna, Andrew M Tonkin, Ingrid Hopper, Amanda G Thrift, Christopher R Levi, Jonathan Sturm, David Durrheim, Joseph Hung, Tom G Briffa, Derek P Chew, Phil Anderson, Lynelle Moon, Mark McEvoy, Philip M Hansbro, David A Newby and John R Attia. Evaluating recruitment strategies for AUSPICE, a large Australian community‐based randomised controlled trial. Med J Aust 2019; 210 (9): 409-415.